Journal of Psychoactive Drugs
2014
David E. Nichols
24 citations
This essay describes the founding of the Heffter Research Institute in 1993 and its development up to the present. The Institute is the only scientific research organization dedicated to scientific research into the medical value of psychedelics, and it has particularly focused on the use of psilocybin. The first clinical treatment study was of the value of psilocybin in obsessive-compulsive...
PLoS One
August 19, 2013
Teri Suzanne Krebs, Pål-ørjan Johansen
338 citations
BACKGROUND: The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or...
Journal of Psychopharmacology
September 20, 2010
Erich Studerus, Michael Kometer, Felix Hasler et al.
529 citations
Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind...
Archives of General Psychiatry
September 7, 2010
Gurpreet S Chopra, Marycie Hagerty, Charles S. Grob et al.
1,220 citations
CONTEXT: Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. OBJECTIVE: To explore the safety and efficacy...
The Journal of Clinical Psychiatry
November 15, 2006
Francisco Moreno, Christopher B. Wiegand, E. Keolani Taitano et al.
786 citations
In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
Psychopharmacology
July 7, 2006
Roland R. Griffiths, William A. Richards, U. Mccann et al.
1,684 citations
RationaleAlthough psilocybin has been used for centuries for religious purposes, little is known scientifically about its acute and persisting effects.ObjectivesThis double-blind study evaluated the acute and longer-term psychological effects of a high dose of psilocybin relative to a comparison compound administered under comfortable, supportive conditions.Materials and methodsThe participants...
Psychopharmacology
February 22, 2001
Jordi Riba, Antoni Rodrı́guez-fornells, Gloria Urbano et al.
302 citations
RationaleAyahuasca is a South American psychoactive beverage that contains the naturally occurring psychedelic agent N,N-dimethyltryptamine (DMT). This "tea" has been used for centuries in religious and medicinal contexts in the rain forest areas of South America and is presently gaining the attention of psychedelic users in North America and Europe.ObjectivesIn the present study, the...
The Tohoku Journal of Experimental Medicine
1986
Morihiro Musha, Atsushi Ishii, Fumio Tanaka et al.
15 citations
Five cases of poisoning by indigenous mushroom Hikageshibiretake (Psilocybe argentipes) are reported. As this mushroom contains psilocybin, in general, clinical features were similar to those seen by pure psilocybin. Acute toxic stuporous state with complete amnesia in the culminating period occurred in one case, psychedelic state with dreamy consciousness in one case and psychotic adverse...